SCHEMBL24596338

SCHEMBL24596338

CCOC(=O)c1ocnc1-c1ccc(C(F)(F)F)nc1Nc1ccccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
ALDH1A1 P00352 3/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
SYK P43405 1/20 0.38
IGF1R P08069 2/20 0.36
SIRT5 Q9NXA8 1/20 0.36
PTK2 Q05397 1/20 0.36
DHODH Q02127 1/20 0.36
TGFBR1 P36897 1/20 0.36
P2RY12 Q9H244 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29789936 0.86 MAPT (0.41) MAPTNPC1CASP3RAB9ASENP8
SCHEMBL24596387 0.86 MAPT (0.41) MAPTNPC1CASP3RAB9ASENP8
SCHEMBL29790079 0.75 SIRT5 (0.39) NPC1RAB9AALDH1A1SYKSIRT5
SCHEMBL24596245 0.75 SIRT5 (0.39) NPC1RAB9AALDH1A1SYKSIRT5
SCHEMBL28874804 0.73 MAPT (0.41) MAPTNPC1CASP3RAB9ASENP8
SCHEMBL24596361 0.73 TGFBR1 (0.41) MAPTALDH1A1SYKTGFBR1
SCHEMBL29790062 0.73 TGFBR1 (0.41) MAPTALDH1A1SYKTGFBR1
SCHEMBL26631694 0.73 BRD4 (0.41) MAPTNPC1RAB9AALDH1A1SYK
SCHEMBL28874816 0.70 FOS (0.57) MAPTNPC1CASP3RAB9ASENP8
SCHEMBL24596365 0.70 BRD4 (0.37) MAPTNPC1RAB9AALDH1A1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A MAPT 466/4885NPC1 1898/4885CASP3 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.